Restatement of Previously Issued Financial Statements - Schedule of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Cash flows from operating activities:
Net income	$ (69,804)	$ 18,930
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	15,469	6,172
Stock-based compensation expense	3,761	5,391
Noncash research and development expense (finance lease)	0	1,441
Noncash operating lease expense	5,904	7,423
Gain from sale of priority review voucher	0	(92,930)
Excess inventory reserve	91	2,583
Other non-cash items	(10)	237
Gain on foreign currency exchange rates	(777)	(108)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(13,528)	(3,689)
Inventory	(7,185)	(5,331)
Operating right of use assets		0
Accounts payable	1,454	1,260
Accrued expenses and other liabilities	(10,299)	(7,206)
Accrued interest payable under finance lease	2,936	915
Operating lease liabilities	(2,844)	(6,361)
Deferred revenue	0	(85)
Net cash used in operating activities	(74,676)	(71,358)
Cash flows from investing activities:
Purchase of property, plant and equipment	(1,775)	(232)
Purchases of marketable securities	0	(19,610)
Proceeds from maturities of marketable securities	0	4,021
Proceeds from sales of marketable securities	0	5,853
Purchase of intangible assets	0	(868)
Proceeds from sale of priority review voucher	0	92,972
Net cash (used in) provided by investing activities	(655)	82,136
Cash flows from financing activities:
Proceeds from exercise of stock options and ESPP contributions	0	7
Principal payments on finance leases	(22,210)	(15,280)
Net cash provided by financing activities	64,645	115,176
(Decrease) increase in cash, cash equivalents and restricted cash	(10,686)	125,954
Cash, cash equivalents and restricted cash at beginning of period	274,597	158,445
Cash, cash equivalents and restricted cash at end of period	263,911	284,399
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	212,047	239,045	$ 221,755
Restricted cash included in other current assets	3,866	1,417
Restricted cash included in restricted cash and other non-current assets	47,998	43,937
Total cash, cash equivalents and restricted cash	263,911	284,399	$ 274,597
Supplemental cash flow disclosures from investing and financing activities:
Purchases of property, plant and equipment included in accounts payable and accrued expenses	0	189
Offering expenses included in accounts payable and accrued expenses		523
Priority review voucher expenses accrued or in accounts payable	0	43
Right-of-use assets obtained in exchange for financial lease liabilities	38,669	(214)
Cash paid during the period for income taxes	1	2
As Previously Reported
Cash flows from operating activities:
Net income		21,240
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization		1,082
Stock-based compensation expense		5,391
Noncash research and development expense (finance lease)		0
Noncash operating lease expense		0
Gain from sale of priority review voucher		(92,930)
Excess inventory reserve		228
Other non-cash items		237
Gain on foreign currency exchange rates		0
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(9,335)
Inventory		(3,586)
Operating right of use assets		11,829
Accounts payable		(6,443)
Accrued expenses and other liabilities		(9,065)
Accrued interest payable under finance lease		0
Operating lease liabilities		(8,001)
Deferred revenue		2,715
Net cash used in operating activities		(86,638)
Cash flows from investing activities:
Purchase of property, plant and equipment		(232)
Purchases of marketable securities		(19,610)
Proceeds from maturities of marketable securities		4,021
Proceeds from sales of marketable securities		5,853
Purchase of intangible assets		(868)
Proceeds from sale of priority review voucher		92,972
Net cash (used in) provided by investing activities		82,136
Cash flows from financing activities:
Proceeds from exercise of stock options and ESPP contributions		7
Principal payments on finance leases		0
Net cash provided by financing activities		130,456
(Decrease) increase in cash, cash equivalents and restricted cash		125,954
Cash, cash equivalents and restricted cash at beginning of period		158,445
Cash, cash equivalents and restricted cash at end of period		284,399
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents		239,045
Restricted cash included in other current assets		1,417
Restricted cash included in restricted cash and other non-current assets		43,937
Total cash, cash equivalents and restricted cash		284,399
Supplemental cash flow disclosures from investing and financing activities:
Purchases of property, plant and equipment included in accounts payable and accrued expenses		189
Offering expenses included in accounts payable and accrued expenses		523
Priority review voucher expenses accrued or in accounts payable		43
Right-of-use assets obtained in exchange for financial lease liabilities		0
Cash paid during the period for income taxes		2
Revision of Prior Period, Error Correction, Adjustment | Adjustments to Embedded Leases
Cash flows from operating activities:
Net income		(2,351)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization		5,131
Stock-based compensation expense		0
Noncash research and development expense (finance lease)		1,441
Noncash operating lease expense		7,423
Gain from sale of priority review voucher		0
Excess inventory reserve		0
Other non-cash items		0
Changes in operating assets and liabilities:
Prepaid expenses and other assets		2,846
Inventory		610
Operating right of use assets		(11,829)
Accounts payable		7,703
Accrued expenses and other liabilities		1,859
Accrued interest payable under finance lease		915
Operating lease liabilities		1,640
Deferred revenue		0
Net cash used in operating activities		15,280
Cash flows from investing activities:
Purchase of property, plant and equipment		0
Purchases of marketable securities		0
Proceeds from maturities of marketable securities		0
Proceeds from sales of marketable securities		0
Purchase of intangible assets		0
Proceeds from sale of priority review voucher		0
Net cash (used in) provided by investing activities		0
Cash flows from financing activities:
Proceeds from exercise of stock options and ESPP contributions		0
Principal payments on finance leases		(15,280)
Net cash provided by financing activities		(15,280)
(Decrease) increase in cash, cash equivalents and restricted cash		0
Cash, cash equivalents and restricted cash at beginning of period		0
Cash, cash equivalents and restricted cash at end of period		0
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents		0
Restricted cash included in other current assets		0
Restricted cash included in restricted cash and other non-current assets		0
Total cash, cash equivalents and restricted cash		0
Supplemental cash flow disclosures from investing and financing activities:
Purchases of property, plant and equipment included in accounts payable and accrued expenses		0
Priority review voucher expenses accrued or in accounts payable		0
Right-of-use assets obtained in exchange for financial lease liabilities		(214)
Revision of Prior Period, Error Correction, Adjustment | Other Adjustments
Cash flows from operating activities:
Net income		41
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization		(41)
Stock-based compensation expense		0
Noncash research and development expense (finance lease)		0
Noncash operating lease expense		0
Gain from sale of priority review voucher		0
Excess inventory reserve		2,355
Other non-cash items		0
Gain on foreign currency exchange rates		0
Changes in operating assets and liabilities:
Prepaid expenses and other assets		2,800
Inventory		(2,355)
Operating right of use assets		0
Accounts payable		0
Accrued expenses and other liabilities		0
Accrued interest payable under finance lease		0
Operating lease liabilities		0
Deferred revenue		(2,800)
Net cash used in operating activities		0
Cash flows from investing activities:
Purchase of property, plant and equipment		0
Purchases of marketable securities		0
Proceeds from maturities of marketable securities		0
Proceeds from sales of marketable securities		0
Purchase of intangible assets		0
Proceeds from sale of priority review voucher		0
Net cash (used in) provided by investing activities		0
Cash flows from financing activities:
Proceeds from exercise of stock options and ESPP contributions		0
Principal payments on finance leases		0
Net cash provided by financing activities		0
(Decrease) increase in cash, cash equivalents and restricted cash		0
Cash, cash equivalents and restricted cash at beginning of period		0
Cash, cash equivalents and restricted cash at end of period		0
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents		0
Restricted cash included in other current assets		0
Restricted cash included in restricted cash and other non-current assets		0
Total cash, cash equivalents and restricted cash		0
Supplemental cash flow disclosures from investing and financing activities:
Purchases of property, plant and equipment included in accounts payable and accrued expenses		0
Offering expenses included in accounts payable and accrued expenses		0
Priority review voucher expenses accrued or in accounts payable		0
Right-of-use assets obtained in exchange for financial lease liabilities		0
Cash paid during the period for income taxes		0
Revision of Prior Period, Error Correction, Adjustment | Error Correction, Leases
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Gain on foreign currency exchange rates		(108)
Supplemental cash flow disclosures from investing and financing activities:
Offering expenses included in accounts payable and accrued expenses		0
Cash paid during the period for income taxes		0
Private Placement
Cash flows from financing activities:
Proceeds from issuance of common stock	0	(196)
Private Placement | As Previously Reported
Cash flows from financing activities:
Proceeds from issuance of common stock		(196)
Private Placement | Revision of Prior Period, Error Correction, Adjustment | Adjustments to Embedded Leases
Cash flows from financing activities:
Proceeds from issuance of common stock		0
Private Placement | Revision of Prior Period, Error Correction, Adjustment | Other Adjustments
Cash flows from financing activities:
Proceeds from issuance of common stock		0
Public Offering
Cash flows from financing activities:
Proceeds from issuance of common stock	$ 0	130,645
Public Offering | As Previously Reported
Cash flows from financing activities:
Proceeds from issuance of common stock		130,645
Public Offering | Revision of Prior Period, Error Correction, Adjustment | Adjustments to Embedded Leases
Cash flows from financing activities:
Proceeds from issuance of common stock		0
Public Offering | Revision of Prior Period, Error Correction, Adjustment | Other Adjustments
Cash flows from financing activities:
Proceeds from issuance of common stock		$ 0